GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biolase Inc (FRA:BTH0) » Definitions » Cyclically Adjusted Revenue per Share

Biolase (FRA:BTH0) Cyclically Adjusted Revenue per Share : €5,511.59 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Biolase Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biolase's adjusted revenue per share for the three months ended in Mar. 2024 was €0.522. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €5,511.59 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biolase's average Cyclically Adjusted Revenue Growth Rate was -23.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -16.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -13.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -12.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biolase was 42.00% per year. The lowest was -16.70% per year. And the median was -0.50% per year.

As of today (2024-05-23), Biolase's current stock price is €0.1564. Biolase's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €5,511.59. Biolase's Cyclically Adjusted PS Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biolase was 1.87. The lowest was 0.01. And the median was 0.31.


Biolase Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biolase's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biolase Cyclically Adjusted Revenue per Share Chart

Biolase Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31,952.60 38,353.50 36,589.60 8,067.25 6,590.33

Biolase Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,511.24 6,788.87 6,863.25 6,590.33 5,511.59

Competitive Comparison of Biolase's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Biolase's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biolase's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biolase's Cyclically Adjusted PS Ratio falls into.



Biolase Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biolase's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.522/131.7762*131.7762
=0.522

Current CPI (Mar. 2024) = 131.7762.

Biolase Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2,499.000 100.560 3,274.765
201409 2,466.500 100.428 3,236.415
201412 2,684.000 99.070 3,570.086
201503 2,006.000 99.621 2,653.485
201506 2,115.000 100.684 2,768.135
201509 2,001.800 100.392 2,627.609
201512 3,331.750 99.792 4,399.587
201603 1,977.400 100.470 2,593.543
201606 2,458.200 101.688 3,185.547
201609 2,357.400 101.861 3,049.737
201612 3,261.250 101.863 4,218.965
201703 2,033.400 102.862 2,604.978
201706 2,245.000 103.349 2,862.507
201709 1,511.000 104.136 1,912.063
201712 1,525.143 104.011 1,932.270
201803 1,015.750 105.290 1,271.273
201806 1,300.500 106.317 1,611.927
201809 1,171.500 106.507 1,449.447
201812 1,433.375 105.998 1,781.967
201903 1,142.375 107.251 1,403.610
201906 850.111 108.070 1,036.596
201909 872.333 108.329 1,061.141
201912 833.091 108.420 1,012.557
202003 333.000 108.902 402.946
202006 173.933 108.767 210.727
202009 168.242 109.815 201.888
202012 179.564 109.897 215.313
202103 126.241 111.754 148.858
202106 126.350 114.631 145.247
202109 132.803 115.734 151.211
202112 180.016 117.630 201.666
202203 148.887 121.301 161.744
202206 189.738 125.017 199.997
202209 159.605 125.227 167.953
202212 170.051 125.222 178.952
202303 29.805 127.348 30.841
202306 24.194 128.729 24.767
202309 8.679 129.860 8.807
202312 3.621 129.419 3.687
202403 0.522 131.776 0.522

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biolase  (FRA:BTH0) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biolase's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.1564/5511.59
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biolase was 1.87. The lowest was 0.01. And the median was 0.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biolase Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biolase's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biolase (FRA:BTH0) Business Description

Industry
Traded in Other Exchanges
Address
27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610
Biolase Inc is a US-based medical device company. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company also markets, sells and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intraoral scanners. It offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

Biolase (FRA:BTH0) Headlines

No Headlines